Open Orphan (LSE:ORPH) Monday saw Open Orphan (LSE:ORPH) strengthen its position in the global fight against Covid-19 with yet more progress in its human challenge activities. The pharma services CRO said the first in-human study of Codagenix’s intranasal SARS-CoV-2...
On Monday, we witnessed one of the craziest days on the market in recent history. What was going up suddenly went down, and what had looked down and out jumped up and came back alive. The trigger was the landmark news that Pfizer and Biontech’s Covid-19 vaccine...
Open Orphan (LSE:ORPH) has confirmed that it is in advanced negotiations with the UK government for a coronavirus challenge study. In a Thursday update in response to a spike in its share price, the pharmaceutical services firm said that any contract signed is...
In the video below, provided by piworld, Paul Fineman and Giles Willits, CEO and CFO of IG Design Group (LSE:IGR), break down the firm’s recent results and walk through its exciting plans for the future. piworld provides content for investors, by investors. The...
Investors are at the accumulation stage with Open Orphan (LSE:ORPH), as shares in the Anglo-Irish contract research organisation hold steady at around 12p. Open Orphan has not seen the same staggering, meteoric rise and crushing fall as other Covid-19 plays like...
